Navigation Links
Novartis Pharmaceuticals Corporation disputes allegations in two US Government lawsuits and looks forward to a fair discussion of the facts
Date:4/26/2013

EAST HANOVER, N.J., April 26, 2013 /PRNewswire/ -- Novartis Pharmaceuticals Corporation (NPC) disputes the allegations made by the US Attorney's Office (USAO) for the Southern District of New York (SDNY) in two complaints filed this week and will defend itself in these litigations. 

"We disagree with the way the government is characterizing our conduct in both of these matters and we stand behind our Compliance program," said Andre Wyss , President, Novartis Pharmaceuticals Corporation and President, Novartis Corporation . "NPC invests significant time and resources to help ensure we conduct our business in an ethical and responsible manner. We are committed to doing it right."

The first suit pertains to a previously disclosed investigation into discounts and rebates to specialty pharmacies for Myfortic®. Discounts and rebates by pharmaceutical companies are a customary, appropriate and legal practice as recognized by the Government itself. NPC believes this suit is a significant expansion of the Anti-Kickback Statute that is inconsistent with law and policy in this area, and threatens to undermine pharmaceutical company discounting practices that benefit both consumers and payers, including the Government. 

The second suit is related to a previously disclosed investigation into speaker programs conducted by NPC for the products Lotrel®, Starlix®and Valturna®. NPC believes the Government's wide-ranging allegations that its speaker programs lacked any legitimate business purpose are without merit. Physician speaker programs are promotional programs designed to inform physicians about the appropriate use of medicines and NPC has numerous controls in place to help ensure they are conducted in a compliant fashion. These programs are an accepted and customary practice in the industry.

As a leading healthcare company, NPC is committed to high standards of ethical business conduct and regulatory compliance in the sale and marketing of its products.  The company's Code of Conduct and policies and procedures guide its associates in their activities and performance.

Disclaimer 
This press release contains expressed or implied forward-looking statements, including statements that can be identified by terminology such as "looks forward to," "will," or similar expressions. Such forward-looking statements reflect the current views of the Group regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results expressed or implied by such statements. These expectations could be affected by, among other things, uncertainties inherent in legal proceedings, and other risks and factors referred to in the Risk Factors section of Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update it in the future.

About Novartis
Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets innovative prescription drugs used to treat a number of diseases and conditions, including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease and respiratory. The company's mission is to improve people's lives by pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 129,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.

Novartis Media Relations

 

Julie Masow

Novartis Media Relations

+1 212 830 2465 (direct)

+1 862 579 8456 (mobile)

julie.masow@novartis.com

 

e-mail: us.mediarelations@novartis.com

Anna Frable

Novartis Pharmaceuticals Corporation

+1 862-778-5388 (direct)

+1 732-673-5262 (mobile)

anna.frable@novartis.com

 

For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis.
For questions about the site or required registration, please contact: journalisthelp@thenewsmarket.com.


'/>"/>
SOURCE Novartis Pharmaceuticals Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Novartis signs on to support Malaria No Mores Power of One campaign to stride towards a future without malaria
2. Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
3. Novartis Pharma Logistics, Inc. voluntarily recalling in Jamaica select lots of certain over-the-counter products due to bottle closure defect
4. Novartis Pharma Logistics, Inc. voluntarily recalling in Trinidad & Tobago select lots of certain over-the-counter products due to bottle closure defect
5. Novartis Pharma Logistics, Inc. voluntarily recalling in Curacao select lots of certain over-the-counter products due to bottle closure defect
6. Novartis Pharma Logistics, Inc. voluntarily recalling in Aruba select lots of certain over-the-counter products due to bottle closure defect
7. Novartis Pharma Logistics, Inc. voluntarily recalling in Barbados select lots of certain over-the-counter products due to bottle closure defect
8. Continued Uptake of Novartis/Incytes Jakafi Will Be the Greatest Driver of Growth in the Myelofibrosis Therapy Market
9. Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at ASH and SABCS
10. Thesan Pharmaceuticals offentliggør første runde af venturefinansieringen ledt af Novo Ventures og Novartis Venture Funds i fællesskab
11. Thesan Pharmaceuticals annuncia un finanziamento di serie A co-gestito da Novo Ventures e Novartis Venture Funds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... YORK , Feb. 17, 2017   Risperdal ... side effects allegedly associated with use of the atypical ... Philadelphia Court of Common Pleas, where ... mass tort program. According to a notice posted on ... to convene a meeting on March 9, 2017 at ...
(Date:2/17/2017)... NEW YORK , Feb. 17, 2017 /PRNewswire/ ... announced today the partnership of their 3D body ... in healthcare IT.  The new integration will be ... on an interactive model of the human body. ... data saves clinicians time, while also increasing the ...
(Date:2/16/2017)... Research and Markets has announced the addition of ... report to their offering. ... Traditional medical devices include devices (e.g., ... implantables, large endoscopes, needle based drug delivery, lab based diagnostics ... to three decades for the treatment and management of various ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... ... been named a finalist in the 8th Annual DecisionHealth Platinum Awards in recognition ... system. Qualis Health’s work is recognized across multiple award categories, highlighting four of ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... cycle management services, announced today that Karen Pilley has been promoted to Chief ... critical in today’s shifting healthcare paradigm – a shift that demands the transition ...
(Date:2/17/2017)... ... 17, 2017 , ... Cancer diagnostics workflow solution provider Inspirata, ... – 22 in San Francisco. As part of the Tri-Conference expo, which is ... solution, as well as its new precision medicine platform, “Crosswalk Insight: Oncology™.” , ...
(Date:2/17/2017)... VA (PRWEB) , ... February 17, 2017 , ... ... protection services and financial planning assistance to families and business owners in and ... for a charity drive to help prevent all forms of domestic violence. , ...
(Date:2/16/2017)... ... February 17, 2017 , ... For some cancer survivors, the ... treatments. Physician researchers at The Marcus Institute of Integrative Health at Thomas ... in reducing symptoms of traumatic stress in cancer patients and published their ...
Breaking Medicine News(10 mins):